KAS
TXG icon

Kestra Advisory Services’s 10x Genomics TXG Stock Holding History

Kestra Advisory Services’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-5,174
Closed -$234K – 2242
2022
Q2 		$234K Buy
5,174
+51
+1% +$2.65K ﹤0.01% 1804
2022
Q1 		$390K Buy
5,123
+124
+2% +$10.8K ﹤0.01% 1429
2021
Q4 		$745K Buy
+4,999
New +$766K 0.01% 1108

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Kestra Advisory Services's TXG Position: Q3 2022 in Review

Kestra Advisory Services sold out of 10x Genomics (TXG) in Q3 2022, closing a stake of 5,174 shares — an estimated $234K sold.

Kestra Advisory Services first reported a position in TXG in Q4 2021 and held it in 3 quarters. The position peaked at $745K in Q4 2021. 233 funds tracked by Wall St. Rank hold TXG as of Q3 2022.

  • Kestra Advisory Services reported no remaining 10x Genomics position as of Q3 2022 after selling out during the quarter.
  • Kestra Advisory Services sold 5,174 10x Genomics shares in Q3 2022, an estimated $234K.
  • Kestra Advisory Services first reported a position in 10x Genomics in Q4 2021 and held it in 3 quarters.
  • Kestra Advisory Services's 10x Genomics position peaked at $745K in Q4 2021.
  • 233 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2022.

Based on Kestra Advisory Services's 13F filing for Q3 2022, filed 1 Nov 2022.